Testing mirabegron for dry age-related macular degeneration
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether mirabegron, a medication commonly used for overactive bladder, can also help people with dry age-related macular degeneration (AMD). It aims to see if the drug can slow down or improve the condition, which currently has no cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged between 50 and 80 years old
- Have early or moderate dry age-related macular degeneration (AMD)
- Have symptoms of overactive bladder
- Best corrected vision in the study eye better than 20/50 (or about 65 letters on an eye chart)
- No conditions that make beta-agonist drugs unsafe (like uncontrolled high blood pressure, irregular heartbeat, kidney or liver failure, allergies to such drugs, or taking certain heart medications)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
This study observes how dry age-related macular degeneration (AMD) progresses over time. It helps doctors learn more about the disease, which may lead to better treatments in the future.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This trial tests a special optical device that may improve vision for people with legally blind dry age-related macular degeneration (AMD). It focuses on improving how well you can see, despite the damage to the center of your retina.
Hear when a new Overactive Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.